You are here

Article Text

Article menu

Download PDFPDF

Professional matters
Review
Implications of recurrent SARS-CoV-2 outbreaks for IBD management
Free
  1. Jonathan P Segal1,
  2. Alan C Moss2
  1. 1 Gastroenterology and Hepatology, St Mary’s Hospital, London, UK
  2. 2 Gastroenterology, BIDMC/Harvard Medical School, Boston, Massachusetts, USA
  1. Correspondence to Dr Jonathan P Segal, Gastroenterology and Hepatology, St Mary's Hospital, London W2 1NY, UK; jonathansegal1{at}nhs.net

Abstract

The initial phases of the global SARS-CoV2 pandemic had significant implications for the management of patients with inflammatory bowel disease (IBD). This impact is likely to be sustained and far-reaching across all models of care. Initial questions about the risk of SARS-CoV2 infection, and COVID-19 complications, in patients taking maintenance anti-TNFs, JAK inhibitors and other immune modulators have preliminary data. Current models for SARS-CoV-2 transmission predict intermittent outbreaks until 2022, which could disrupt clinical care and negatively affect outcomes for many patients across the globe. This review summarises changes in IBD clinical practice that will be required during the ‘post-peak’ phase of viral pandemics.

  • IBD
  • epidemiology

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

https://doi.org/10.1136/flgastro-2020-101531

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors JPS and ACM wrote the manuscript and contributed equally. Both approved final version.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests Both are on the editorial board on Frontline Gastroenterology.

    • Provenance and peer review Not commissioned; externally peer reviewed.